2024-11-13 - Analysis Report
## Merck & Co. Inc (MRK) Stock Analysis Report

**Company Overview:**  Merck & Co. Inc is a global pharmaceutical company that researches, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

**1. Performance Comparison:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) | Cumulative Return (MRK) | Cumulative Return (VOO) | Return Difference | Relative Divergence |
|------------|------|-------|------|-------|---------|------------------------|--------------------------|-------------------|---------------------|
| 2015-2017  | 8.2% | 17.4% | -30.2% | 0.9 | 135.8 | N/A                  | N/A                    | N/A                | N/A                 |
| 2016-2018  | 59.7% | 17.1% | 27.4% | 0.7 | 184.4 | N/A                  | N/A                    | N/A                | N/A                 |
| 2017-2019  | 65.0% | 17.1% | 13.3% | 0.7 | 219.5 | N/A                  | N/A                    | N/A                | N/A                 |
| 2018-2020  | 58.9% | 26.7% | 11.6% | 0.7 | 197.4 | N/A                  | N/A                    | N/A                | N/A                 |
| 2019-2021  | 16.7% | 26.7% | -83.3% | 0.6 | 193.9 | N/A                  | N/A                    | N/A                | N/A                 |
| 2020-2022  | 39.4% | 26.7% | 15.8% | 0.5 | 280.7 | N/A                  | N/A                    | N/A                | N/A                 |
| 2021-2023  | 55.2% | 19.9% | 20.2% | 0.3 | 275.8 | N/A                  | N/A                    | N/A                | N/A                 |
| 2022-2024  | 38.8% | 24.6% | 8.3% | 0.3 | 254.8 | 94.14%                | 179.55%               | -85.41%            | 1.81%               |

**Analysis:** Over the past years, MRK has significantly lagged the S&P 500 (VOO). The cumulative return of MRK is 94.14% compared to VOO's 179.55%. The current return difference is -85.41%, indicating that MRK has underperformed by approximately 85% compared to the market benchmark. The relative divergence of 1.81% suggests that the current underperformance is relatively low compared to its historical range. 

**2. Recent Price Movements:**

* Closing Price: 98.64 (Last Market: 98.65)
* 5-Day Moving Average: 100.84
* 20-Day Moving Average: 104.14
* 60-Day Moving Average: 110.9

**Analysis:** The stock price is currently below its 5-day, 20-day, and 60-day moving averages, indicating a downtrend.

**3. Technical Indicators:**

* RSI: 23.88
* PPO: -0.16
* Delta_Previous_Relative_Divergence: -25.55 (-) (Short-term Downtrend)
* Expected Return: 0.0% (Long-term Expected Return)

**Analysis:** The RSI indicates that the stock is currently in oversold territory. The PPO confirms a downtrend. The recent relative divergence suggests a short-term decline. While the current price is not significantly higher or lower than the last market price, it indicates a potential for slight upward movement. The expected return is 0.0%, meaning that in the long term, the stock is not expected to outperform the S&P 500.

**4. Recent Earnings and Forecasts:**

| Date       | EPS    | Revenue  |
|------------|--------|---------|
| 2024-11-06 | 1.25   | 16.66 B$ |
| 2024-08-05 | 2.15   | 16.11 B$ |
| 2024-05-03 | 1.88   | 15.78 B$ |
| 2023-11-03 | 1.87   | 15.96 B$ |
| 2024-11-06 | 1.87   | 15.96 B$ |

**Analysis:** The most recent earnings report (2024-11-06) showed EPS of 1.25 and revenue of 16.66 B$.  (Please provide the expected EPS and revenue for 2024-11-06 so that the actual results can be compared). Overall, earnings have been relatively stable, indicating a consistent performance. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter       | Revenue  | Profit Margin |
|---------------|---------|--------------|
| 2024-09-30 | $16.66B | 75.51%       |
| 2024-06-30 | $16.11B | 76.76%       |
| 2024-03-31 | $15.78B | 77.56%       |
| 2023-12-31 | $14.63B | 73.26%       |
| 2023-09-30 | $15.96B | 73.29%       |

**2) Capital and Profitability:**

| Quarter       | Equity   | ROE     |
|---------------|---------|---------|
| 2024-09-30 | $44.50B | 7.09%   |
| 2024-06-30 | $43.58B | 12.52%  |
| 2024-03-31 | $40.36B | 11.80%  |
| 2023-12-31 | $37.58B | -3.26%  |
| 2023-09-30 | $41.25B | 11.50%  |

**Analysis:** Merck demonstrates consistently high revenue and profitability with a strong profit margin, indicating a solid financial position. ROE has shown some fluctuations but generally indicates a profitable company.

**6. News and Recent Developments:**

* Please provide recent news articles about MRK's earnings reports within the last two days (especially from sources like Shacknews, etc.) and include details about the company's financial performance.
* Please mention the recent market outlook for MRK and relevant analysis from credible sources like FINBOLD.
* Include analyst opinions and performance highlights for MRK.

**7. Overall Analysis:**

MRK has lagged the market significantly in recent years and is currently in a downtrend. The technical indicators suggest an oversold condition and potential for short-term price movement. The expected long-term return is not expected to outperform the market. However, the company has a strong financial position with consistent revenue and profitability.  Further analysis should consider recent news and analyst opinions to get a more complete picture of the current market conditions and future prospects for MRK. 

**Disclaimer:** This report is for informational purposes only and should not be considered as financial advice. It is highly recommended to conduct thorough research and consult with a financial professional before making any investment decisions. 
